Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-27032026-271326
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 1521]
NEW DELHI, WEDNESDAY, MARCH 25, 2026/ CHAITRA 4, 1948
2203 GI/2026
2
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II-SEC. 3(ii)]
[PART II-SEC. 3(ii)] 3
4
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II-SEC. 3(ii)]
[का. सं./276/144/2026/एफ/ फा. सं. 8(144)/2026/डीपी/एनपीपीए-डिवी-II]
BHIVA RAM YADAV, Assistant Director
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 25th March, 2026
S.O. 1586(E).— In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of
the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. No. 1486(E) dated 27.03.2025, 3976(E) dated 29.08.2025 and 5021(E) dated 04.11.2025 in so far as it
relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B
for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession,
the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2025
as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax
applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said
Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in
columns (3) and (4) thereof:
Table A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.64956% increase.
+-------+-----------------+---------------------------------------------+---------+--------------------+
| SI No | Medicines | Dosage form and Strength | Unit | Ceiling price |
| | | | | (w.e.f. 1.4.2026 |
| | | | | with WPI @ |
| | | | | 0.64956%) (in Rs.) |
+=======+=================+=============================================+=========+====================+
| (1) | (2) | (3) | (4) | (5) |
+-------+-----------------+---------------------------------------------+---------+--------------------+
| 1. | Metronidazole | Injection (0.5%w/v) /500mg/100ml in 100ml | Per ml | 0.25 |
| | | pack for packages in non-glass with special | | |
| | | features | | |
+-------+-----------------+---------------------------------------------+---------+--------------------+
| 2. | Mannitol | Injection 20% in 100 ml pack for packages in| Per ml | 0.41 |
| | | non-glass with special features | | |
+-------+-----------------+---------------------------------------------+---------+--------------------+
| 3. | Mannitol | Injection 20% in 350 ml pack for packages in| Per ml | 0.41 |
| | | non-glass with special features | | |
+-------+-----------------+---------------------------------------------+---------+--------------------+
| 4. | Dextrose | Injection (25% w/v) in 100 ml pack for | Per ml | 0.24 |
| | (Glucose) | packages in non-glass with special | | |
| | | features | | |
+-------+-----------------+---------------------------------------------+---------+--------------------+
| 5. | Dextrose | Injection (25% w/v) in 500 ml pack for | Per ml | 0.24 |
| | (Glucose) | packages in non-glass with special | | |
| | | features | | |
+-------+-----------------+---------------------------------------------+---------+--------------------+
| 6. | Ciprofloxacin | Injection 200mg/100ml in 100 ml pack for | Per ml | 0.23 |
| | | packages in non-glass with special | | |
| | | features | | |
+-------+-----------------+---------------------------------------------+---------+--------------------+
TABLE 'B'
+-------+-------------------------------------------------------+------------------------------------+
| Sl. No.| Name of Manufacturer | Product /Brand Name |
+=======+=======================================================+====================================+
| (1) | (2) | (3) |
+-------+-------------------------------------------------------+------------------------------------+
| 1. | M/s Otsuka Pharmaceutical India Private Ltd. [Note (b)| Eurohead bottle |
| | below] | |
+-------+-------------------------------------------------------+------------------------------------+
| 2. | M/s Denis Chem Lab Ltd. [Note (b) below] | Eurohead Propylene Bottle |
+-------+-------------------------------------------------------+------------------------------------+
| 3. | M/s Rusoma Laboratories Pvt. Ltd. [Note (b) below] | Eurohead FFS Bottle |
+-------+-------------------------------------------------------+------------------------------------+
| 4. | M/s Sachin Parenteral Pvt. Ltd. [Note (b) below] | SAFE PORT |
+-------+-------------------------------------------------------+------------------------------------+
| 5. | M/s Biosynergy Lifecare Pvt. Ltd. [Note (b) below] | BIOPORT |
+-------+-------------------------------------------------------+------------------------------------+
| 6. | M/s Promea Therapeutics Pvt. Ltd. [Note (c) below] | PROCAP-MT, PROCAP-D25 |
+-------+-------------------------------------------------------+------------------------------------+
| 7. | M/s Aculife Healthcare Pvt. Ltd. | Euro head Plastic Bottle (FFS |
| | | Technology) |
+-------+-------------------------------------------------------+------------------------------------+
| 8. | M/s Puniska Injectables Pvt. Ltd. [Note (d) below] | Plastic Bottle with Euro Head cap |
+-------+-------------------------------------------------------+------------------------------------+
| 9. | M/s Jedux Parenteral Pvt. Ltd. [Note (e) below] | JEDUX Double port with Euro Head, |
| | | JPORT Plus |
+-------+-------------------------------------------------------+------------------------------------+
| 10. | M/s Hindustan Polyfab [Note (f) below] | Euro Head /LDPE Bottles |
+-------+-------------------------------------------------------+------------------------------------+
| 11. | M/s Pharma Implex Laboratories Pvt. Ltd. [Note (g) | Euro Cap/Head Bottles |
| | below] | |
+-------+-------------------------------------------------------+------------------------------------+
| 12. | M/s IV Tech Healthcare [Note (b) below] | Twin Port Euro Head Bottles |
+-------+-------------------------------------------------------+------------------------------------+
| 13. | M/s Life Infusion Pharmaceuticals Pvt. Ltd. [Note (g)| Dual Port Plastic (PP) Bottles |
| | below] | |
+-------+-------------------------------------------------------+------------------------------------+
Note:
(a) The ceiling prices are applicable with effect from 1.4.2026 (ceiling prices are inclusive of Wholesale Price Index
(WPI) @ 0.64956% for the year 2025 over 2024).
(b) In case of M/s Otsuka Pharmaceutical India Private Ltd. (Sl. No. 1 of Table B), M/s Denis Chem Lab Ltd. (Sl. No.
2 of Table B), M/s Rusoma Laboratories Pvt. Ltd. (Sl. No. 3 of Table B), M/s Sachin Parenteral Pvt. Ltd. (Sl. No.
4 of Table B), M/s Biosynergy Lifecare Pvt. Ltd. (Sl. No. 5 of Table B) and M/s IV Tech Healthcare (Sl. No. 12
of Table B), only the prices of the formulations specified in Sl. No. 1, 2 & 4 of Table A are applicable.
(c) In case of M/s Promea Therapeutics Pvt. Ltd. (Sl. No. 6 of Table B), only the prices of the formulations specified
in Sl. No. 1 & 4 of Table A are applicable.
(d) In case of M/s Puniska Injectables Pvt. Ltd. (Sl. No. 8 of Table B), only the prices of the formulation specified in
Sl. No. 1 of Table A are applicable.
(e) In case of M/s Jedux Parenteral Pvt. Ltd. (Sl. No. 9 of Table B), only the prices of the formulations specified in Sl.
No. 1, 2, 4, 5 & 6 of Table A are applicable.
(f) In case of M/s Hindustan Polyfab (Sl. No. 10 of Table B), only the prices of the formulations specified at Sl. No.
1 & 6 of Table A are applicable.
(g) In case of M/s Pharma Implex Laboratories Pvt. Ltd. (Sl. No. 11 of Table B) and M/s Life Infusion Pharmaceuticals
Pvt. Ltd. (Sl. No. 13 of Table B), only the prices of the formulations specified at Sl. No. 1, 2, 4 & 6 of Table A are
applicable.
(h) The manufacturers of scheduled formulations, selling abovesaid products/brands of scheduled formulations at
price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the
Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified
in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(i) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified
vide S.O. No. 1486(E) dated 27.03.2025, 3976(E) dated 29.08.2025 and 5021(E) dated 04.11.2025 (plus Goods
and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI
@0.64956% for year 2025 over 2024 in accordance with paragraph 16(2) of DPCO, 2013.
(j) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(k) Any other manufacturer claiming separate ceiling price for non-glass with special feature shall apply to NPPA
for separate ceiling price approval along with documents and shall demonstrate such pack.
(l) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned
manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price
(MRP), along with interest thereon from the date of overcharging.
(m) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph
11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug
Controller and dealers.
(n) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list,
if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a
manner so as to be easily accessible to any person wishing to consult the same.
(o) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above
table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for
prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(p) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through
IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish
information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in
Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(q) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit
the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013
read with Essential Commodities Act, 1955.
(r) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this
notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification,
stand(s) superseded.
[PN/276/144/2026/F /F. No. 8(144)/2026/D.P./NPPA-Div.-II ]
BHIVA RAM YADAV, Assistant Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.
GORAKHA NATH
YADAVA
Digitally signed by GORAKHA NATH
YADAVA
Date: 2026.03.27 16:32:57 +05'30'
Login to read full text